-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Thanks to the concentration of high-quality medical resources, the three cities of Beijing, Shanghai, and Guangzhou have always been the “big households” of domestic drug sales
.
According to data from Mi Nei.
com, in the 2021H1 key city public hospital chemical city pattern, the sales of Beijing, Shanghai and Guangzhou each exceeded 9 billion yuan, ranking firmly in the top three
.
Factors such as centralized procurement and medical insurance negotiations have brought about a new market pattern.
Anti-tumor drugs are still the main drug in the three cities of Beijing, Shanghai and Guangzhou; Lipitor has grown against the trend, lung cancer star drugs have declined for the first time, and the sales of the three major brands have doubled; Zhu, CSPC, Qilu, Yangtze River.
.
.
Domestic brands are on the list
.
.
According to data from Mi Nei.
com, in the 2021H1 key city public hospital chemical city pattern, the sales of Beijing, Shanghai and Guangzhou each exceeded 9 billion yuan, ranking firmly in the top three
.
Factors such as centralized procurement and medical insurance negotiations have brought about a new market pattern.
Anti-tumor drugs are still the main drug in the three cities of Beijing, Shanghai and Guangzhou; Lipitor has grown against the trend, lung cancer star drugs have declined for the first time, and the sales of the three major brands have doubled; Zhu, CSPC, Qilu, Yangtze River.
.
.
Domestic brands are on the list
.
2021H1 Beijing, Shanghai, and Guangzhou public hospitals terminal chemical drug city layout (unit: 100 million yuan)
Source: Mi Nei.
com's chemical drug terminal competition pattern in key cities of public hospitals
com's chemical drug terminal competition pattern in key cities of public hospitals
Beijing: Lipitor's "hard carry", lung cancer star drug plummets by 15%
Annual sales trend of terminal chemical drugs in Beijing public hospitals (unit: 100 million yuan)
Source: Mi Nei.
com's chemical drug terminal competition pattern in key cities of public hospitals
com's chemical drug terminal competition pattern in key cities of public hospitals
According to data from Mi Nei.
com, in 2021H1, the sales of terminal chemical drugs in Beijing public hospitals are close to 10 billion yuan, an increase of 27.
99% year-on-year, the most impressive increase among the three major cities
.
From the perspective of the treatment field, the TOP3 sales categories are anti-tumor and immunomodulators, digestive system and metabolic drugs, and systemic anti-infective drugs, which account for 23.
37%, 13.
69%, and 12.
5% respectively
.
com, in 2021H1, the sales of terminal chemical drugs in Beijing public hospitals are close to 10 billion yuan, an increase of 27.
99% year-on-year, the most impressive increase among the three major cities
.
From the perspective of the treatment field, the TOP3 sales categories are anti-tumor and immunomodulators, digestive system and metabolic drugs, and systemic anti-infective drugs, which account for 23.
37%, 13.
69%, and 12.
5% respectively
.
2021H1 Beijing Public Hospital Top 10 Chemical Drug Brands
Source: Mi Nei.
com's chemical drug terminal competition pattern in key cities of public hospitals
com's chemical drug terminal competition pattern in key cities of public hospitals
In the TOP10 brand, there are 6 anti-tumor drugs, and 1 systemic antibacterial drug, antithrombotic drug, blood substitute and perfusion fluid, and blood lipid regulator
.
Sumitomo's antibacterial drug meropenem for injection jumped to the top of the list, Sanofi's oxaliplatin for injection, Roche's rituximab injection, and CSPC Ouyi's doxorubicin hydrochloride liposome injection were sold.
The volume growth exceeded 50%
.
.
Sumitomo's antibacterial drug meropenem for injection jumped to the top of the list, Sanofi's oxaliplatin for injection, Roche's rituximab injection, and CSPC Ouyi's doxorubicin hydrochloride liposome injection were sold.
The volume growth exceeded 50%
.
Meropenem for injection, which ranks first on the list, is a carbapenem antibiotic.
It is mainly suitable for adults and children with infections caused by single or multiple meropenem-sensitive bacteria, including pneumonia, urinary tract infections, intra-abdominal infections, Gynecological infections and so on
.
It is worth noting that 4 companies that have evaluated the consistency of meropenem for injection, including Joincare , Hisun Pharmaceutical, CSPC and North China Pharmaceutical, are expected to be included in the next batch of generic drugs
.
It is mainly suitable for adults and children with infections caused by single or multiple meropenem-sensitive bacteria, including pneumonia, urinary tract infections, intra-abdominal infections, Gynecological infections and so on
.
It is worth noting that 4 companies that have evaluated the consistency of meropenem for injection, including Joincare , Hisun Pharmaceutical, CSPC and North China Pharmaceutical, are expected to be included in the next batch of generic drugs
.
Pfizer's Lipitor (Atorvastatin calcium) stubbornly held the third place
.
Since atorvastatin was included in the first batch of centralized procurement in 2018, the scale of the domestic market has been declining
.
Although Lipitor did not win the bid, Pfizer successfully maintained its leading position in the domestic market by reforming its marketing model
.
.
Since atorvastatin was included in the first batch of centralized procurement in 2018, the scale of the domestic market has been declining
.
Although Lipitor did not win the bid, Pfizer successfully maintained its leading position in the domestic market by reforming its marketing model
.
AstraZeneca's Teresa (osimertinib mesylate tablets) 2021H1 sales fell 14.
62% year-on-year
.
Teresa is the world's first third-generation advanced lung cancer targeted drug.
In 2018, its price was reduced by 70% and entered the national medical insurance negotiation catalog.
The price is 15,300 yuan per box/(80mg*30 tablets); Osimitinib first-line indications in 2020 Entering medical insurance, the price is reduced by 64% to 5580 yuan/box on the original basis
.
After the initial explosive growth, osimertinib experienced negative growth in the domestic market for the first time under the influence of price cuts and competing products
.
62% year-on-year
.
Teresa is the world's first third-generation advanced lung cancer targeted drug.
In 2018, its price was reduced by 70% and entered the national medical insurance negotiation catalog.
The price is 15,300 yuan per box/(80mg*30 tablets); Osimitinib first-line indications in 2020 Entering medical insurance, the price is reduced by 64% to 5580 yuan/box on the original basis
.
After the initial explosive growth, osimertinib experienced negative growth in the domestic market for the first time under the influence of price cuts and competing products
.
Shanghai: PPI injections soared 467%! Livzon, Yangtze River, Sansheng on the list
Annual sales trend of terminal chemical drugs in Shanghai public hospitals (unit: 100 million yuan)
Source: Mi Nei.
com's chemical drug terminal competition pattern in key cities of public hospitals
com's chemical drug terminal competition pattern in key cities of public hospitals
According to data from Mi Nei.
com, the sales of terminal chemical drugs in Shanghai public hospitals in 2021H1 exceeded 9 billion yuan, a year-on-year increase of 3.
61%
.
From the perspective of the therapeutic field, the TOP3 sales categories are anti-tumor and immune modulators, digestive system and metabolic drugs, and systemic anti-infective drugs, accounting for 23.
04%, 15.
43%, and 13.
96% respectively
.
com, the sales of terminal chemical drugs in Shanghai public hospitals in 2021H1 exceeded 9 billion yuan, a year-on-year increase of 3.
61%
.
From the perspective of the therapeutic field, the TOP3 sales categories are anti-tumor and immune modulators, digestive system and metabolic drugs, and systemic anti-infective drugs, accounting for 23.
04%, 15.
43%, and 13.
96% respectively
.
2021H1 Shanghai Public Hospital's Top 10 Chemical Drug Brands
Source: Mi Nei.
com's chemical drug terminal competition pattern in key cities of public hospitals
com's chemical drug terminal competition pattern in key cities of public hospitals
Among the TOP10 brands, there are 4 anti-tumor drugs, and 2 plasma substitutes and infusions
.
From the perspective of sales changes, the sales of Livzon Group’s ilaprazole sodium for injection soared 466.
95%, Sanofi’s oxaliplatin for injection rose by more than 100%; sales of five brands declined, and Roche’s All three monoclonal antibodies are involved
.
.
From the perspective of sales changes, the sales of Livzon Group’s ilaprazole sodium for injection soared 466.
95%, Sanofi’s oxaliplatin for injection rose by more than 100%; sales of five brands declined, and Roche’s All three monoclonal antibodies are involved
.
Sanofi's leroxatin (oxaliplatin for injection) ranked first, with sales in 2021H1 increasing by 107.
58% year-on-year; Bayer's Xarelto (rivaroxaban tablets) ranked third, with 2021H1 sales increasing year-on-year 13.
04%
.
Oxaliplatin and rivaroxaban are the fifth batch of collectively harvested varieties.
Sanofi’s oxadine won the bid with the highest price, while Bayer’s Xarelto abandoned the bid.
In the end, many companies won the bid for rivaroxaban.
Up to 13 companies
.
With the implementation of the fifth batch of centralized procurement, the market structure of oxaliplatin and rivaroxaban will be reshuffled
.
58% year-on-year; Bayer's Xarelto (rivaroxaban tablets) ranked third, with 2021H1 sales increasing year-on-year 13.
04%
.
Oxaliplatin and rivaroxaban are the fifth batch of collectively harvested varieties.
Sanofi’s oxadine won the bid with the highest price, while Bayer’s Xarelto abandoned the bid.
In the end, many companies won the bid for rivaroxaban.
Up to 13 companies
.
With the implementation of the fifth batch of centralized procurement, the market structure of oxaliplatin and rivaroxaban will be reshuffled
.
Ilaprazole is a proton pump inhibitor and is currently the strongest class of drugs that inhibit gastric acid secretion
.
As the exclusive innovative drug of Livzon Group, ilaprazole enteric-coated tablets have been included in the national medical insurance category B, and ilaprazole sodium for injection entered the national medical insurance negotiation catalog at the end of 2019
.
In recent years, the market size of ilaprazole has continued to rise, and it has grown into a large variety of 1 billion yuan in Livzon Group
.
.
As the exclusive innovative drug of Livzon Group, ilaprazole enteric-coated tablets have been included in the national medical insurance category B, and ilaprazole sodium for injection entered the national medical insurance negotiation catalog at the end of 2019
.
In recent years, the market size of ilaprazole has continued to rise, and it has grown into a large variety of 1 billion yuan in Livzon Group
.
In addition to Livzon Group’s ilaprazole sodium for injection, the domestic brands on the list include Yangtze River Pharmaceutical’s Dezocine Injection and 3SBio’s Terpio (recombinant human thrombopoietin injection)
.
Dezocine is a powerful opioid analgesic used for all kinds of pain that require opioid analgesics
.
TPIAO is the only recombinant human thrombopoietin (rhTPO) product in the world today.
The semi-annual report of 3SBio shows that TPIAO's sales in 2021H1 exceeded 1.
5 billion yuan, an increase of 10.
7% year-on-year
.
.
Dezocine is a powerful opioid analgesic used for all kinds of pain that require opioid analgesics
.
TPIAO is the only recombinant human thrombopoietin (rhTPO) product in the world today.
The semi-annual report of 3SBio shows that TPIAO's sales in 2021H1 exceeded 1.
5 billion yuan, an increase of 10.
7% year-on-year
.
Guangzhou: Sales of breast cancer "magic drug" soared by 120% ! Qilu and Shiyao are on the list
Annual sales trend of terminal chemical drugs in public hospitals in Guangzhou (unit: 100 million yuan)
Source: Mi Nei.
com's chemical drug terminal competition pattern in key cities of public hospitals
com's chemical drug terminal competition pattern in key cities of public hospitals
According to data from Mi Nei.
com, the terminal chemical drug sales of public hospitals in Guangzhou in 2021H1 are close to 10 billion yuan, a year-on-year increase of 17.
07% and a year-on-year decline of more than 10%
.
From the perspective of the treatment field, the TOP3 sales categories are anti-tumor and immunomodulators, digestive system and metabolic drugs, blood and hematopoietic system drugs, accounting for 31.
79%, 13.
82%, and 12.
44% respectively
.
com, the terminal chemical drug sales of public hospitals in Guangzhou in 2021H1 are close to 10 billion yuan, a year-on-year increase of 17.
07% and a year-on-year decline of more than 10%
.
From the perspective of the treatment field, the TOP3 sales categories are anti-tumor and immunomodulators, digestive system and metabolic drugs, blood and hematopoietic system drugs, accounting for 31.
79%, 13.
82%, and 12.
44% respectively
.
2021H1 Guangzhou Public Hospital Terminal Chemical Drug Brand Top 10
Source: Mi Nei.
com's chemical drug terminal competition pattern in key cities of public hospitals
com's chemical drug terminal competition pattern in key cities of public hospitals
Among the TOP10 brands, there are 6 anti-tumor drugs, and 1 systemic antibacterial drug, hemostatic drug, blood substitute and perfusion fluid, and immunostimulant
.
The TOP5 brands are all anti-tumor drugs, and the sales of Sanofi’s oxaliplatin and AstraZeneca’s osimertinib both exceeded 100 million yuan
.
Roche still has 3 monoclonal antibodies on the list, the difference is that Pertuzumab replaced rituximab
.
.
The TOP5 brands are all anti-tumor drugs, and the sales of Sanofi’s oxaliplatin and AstraZeneca’s osimertinib both exceeded 100 million yuan
.
Roche still has 3 monoclonal antibodies on the list, the difference is that Pertuzumab replaced rituximab
.
Roche's breast cancer targeted drug Pattuzumab (Pertuzumab injection) squeezed into the TOP10 for the first time, and sales in 2021H1 increased by 122.
65% year-on-year
.
Pertuzumab is a second-generation targeted drug for HER2-positive breast cancer.
It was approved for marketing in China at the end of 2018 and entered the National Medical Insurance Negotiation List at the end of 2019.
The price is 4955 yuan per tube (420mg/14ml), which is more included in medical insurance.
Compared with the previous 18,800 yuan/branch, a decrease of 74%
.
Medical insurance negotiations promote the rapid increase in volume of this product.
In 2020, the sales of Pertuzumab in public hospitals in Guangzhou will increase by more than 4200%
.
65% year-on-year
.
Pertuzumab is a second-generation targeted drug for HER2-positive breast cancer.
It was approved for marketing in China at the end of 2018 and entered the National Medical Insurance Negotiation List at the end of 2019.
The price is 4955 yuan per tube (420mg/14ml), which is more included in medical insurance.
Compared with the previous 18,800 yuan/branch, a decrease of 74%
.
Medical insurance negotiations promote the rapid increase in volume of this product.
In 2020, the sales of Pertuzumab in public hospitals in Guangzhou will increase by more than 4200%
.
The domestic brands on the list include Qilu Pharmaceutical's Xinruibai (pegylated recombinant human granulocyte stimulating factor injection) and CSPC Ouyi's Domesu (doxorubicin hydrochloride liposome injection)
.
.
Pegylated recombinant human granulocyte stimulating factor injection is a long-acting baiyao.
According to data from Meinenet, the domestic long-acting baiyao market has continued to rise in recent years.
Currently, the product manufacturers include Qilu Pharmaceutical and CSPC.
, Hengrui Pharmaceutical , and New Times Pharmaceutical
.
According to data from Meinenet, the domestic long-acting baiyao market has continued to rise in recent years.
Currently, the product manufacturers include Qilu Pharmaceutical and CSPC.
, Hengrui Pharmaceutical , and New Times Pharmaceutical
.
Doxorubicin hydrochloride is an anthracycline antibiotic and a broad-spectrum anti-tumor drug.
It is mainly used for chemotherapy of multiple myeloma, lymphoma, ovarian cancer, and breast cancer
.
Doxorubicin Hydrochloride Liposome Injection is a high-end nano-preparation, and currently only three domestic companies have been approved for production, including CSPC Ouyi, Changzhou Jinyuan Pharmaceutical and Fudan Zhangjiang
.
Among them, CSPC Ouyi is the first company that has reviewed this product
.
It is mainly used for chemotherapy of multiple myeloma, lymphoma, ovarian cancer, and breast cancer
.
Doxorubicin Hydrochloride Liposome Injection is a high-end nano-preparation, and currently only three domestic companies have been approved for production, including CSPC Ouyi, Changzhou Jinyuan Pharmaceutical and Fudan Zhangjiang
.
Among them, CSPC Ouyi is the first company that has reviewed this product
.
Thanks to the concentration of high-quality medical resources, the three cities of Beijing, Shanghai, and Guangzhou have always been the “big households” of domestic drug sales
.
According to data from Mi Nei.
com, in the 2021H1 key city public hospital chemical city pattern, the sales of Beijing, Shanghai and Guangzhou each exceeded 9 billion yuan, ranking firmly in the top three
.
Factors such as centralized procurement and medical insurance negotiations have brought about a new market pattern.
Anti-tumor drugs are still the main drug in the three cities of Beijing, Shanghai and Guangzhou; Lipitor has grown against the trend, lung cancer star drugs have declined for the first time, and the sales of the three major brands have doubled; Zhu, CSPC, Qilu, Yangtze River.
.
.
Domestic brands are on the list
.
.
According to data from Mi Nei.
com, in the 2021H1 key city public hospital chemical city pattern, the sales of Beijing, Shanghai and Guangzhou each exceeded 9 billion yuan, ranking firmly in the top three
.
Factors such as centralized procurement and medical insurance negotiations have brought about a new market pattern.
Anti-tumor drugs are still the main drug in the three cities of Beijing, Shanghai and Guangzhou; Lipitor has grown against the trend, lung cancer star drugs have declined for the first time, and the sales of the three major brands have doubled; Zhu, CSPC, Qilu, Yangtze River.
.
.
Domestic brands are on the list
.
2021H1 Beijing, Shanghai, and Guangzhou public hospitals terminal chemical drug city layout (unit: 100 million yuan)
Hospital Source: Mi Nei.
com's chemical drug terminal competition pattern in key cities of public hospitals
com's chemical drug terminal competition pattern in key cities of public hospitals
Beijing: Lipitor's "hard carry", lung cancer star drug plummets by 15%
Beijing: Lipitor's "hard carry", lung cancer star drug plummets by 15% Annual sales trend of terminal chemical drugs in Beijing public hospitals (unit: 100 million yuan)
Source: Mi Nei.
com's chemical drug terminal competition pattern in key cities of public hospitals
com's chemical drug terminal competition pattern in key cities of public hospitals
According to data from Mi Nei.
com, in 2021H1, the sales of terminal chemical drugs in Beijing public hospitals are close to 10 billion yuan, an increase of 27.
99% year-on-year, the most impressive increase among the three major cities
.
From the perspective of the treatment field, the TOP3 sales categories are anti-tumor and immunomodulators, digestive system and metabolic drugs, and systemic anti-infective drugs, which account for 23.
37%, 13.
69%, and 12.
5% respectively
.
com, in 2021H1, the sales of terminal chemical drugs in Beijing public hospitals are close to 10 billion yuan, an increase of 27.
99% year-on-year, the most impressive increase among the three major cities
.
From the perspective of the treatment field, the TOP3 sales categories are anti-tumor and immunomodulators, digestive system and metabolic drugs, and systemic anti-infective drugs, which account for 23.
37%, 13.
69%, and 12.
5% respectively
.
2021H1 Beijing Public Hospital Top 10 Chemical Drug Brands
Source: Mi Nei.
com's chemical drug terminal competition pattern in key cities of public hospitals
com's chemical drug terminal competition pattern in key cities of public hospitals
In the TOP10 brand, there are 6 anti-tumor drugs, and 1 systemic antibacterial drug, antithrombotic drug, blood substitute and perfusion fluid, and blood lipid regulator
.
Sumitomo's antibacterial drug meropenem for injection jumped to the top of the list, Sanofi's oxaliplatin for injection, Roche's rituximab injection, and CSPC Ouyi's doxorubicin hydrochloride liposome injection were sold.
The volume growth exceeded 50%
.
.
Sumitomo's antibacterial drug meropenem for injection jumped to the top of the list, Sanofi's oxaliplatin for injection, Roche's rituximab injection, and CSPC Ouyi's doxorubicin hydrochloride liposome injection were sold.
The volume growth exceeded 50%
.
Meropenem for injection, which ranks first on the list, is a carbapenem antibiotic.
It is mainly suitable for adults and children with infections caused by single or multiple meropenem-sensitive bacteria, including pneumonia, urinary tract infections, intra-abdominal infections, Gynecological infections and so on
.
It is worth noting that 4 companies that have evaluated the consistency of meropenem for injection, including Joincare , Hisun Pharmaceutical, CSPC and North China Pharmaceutical, are expected to be included in the next batch of generic drugs
.
Children's Children's Health healthIt is mainly suitable for adults and children with infections caused by single or multiple meropenem-sensitive bacteria, including pneumonia, urinary tract infections, intra-abdominal infections, Gynecological infections and so on
.
It is worth noting that 4 companies that have evaluated the consistency of meropenem for injection, including Joincare , Hisun Pharmaceutical, CSPC and North China Pharmaceutical, are expected to be included in the next batch of generic drugs
.
Pfizer's Lipitor (Atorvastatin calcium) stubbornly held the third place
.
Since atorvastatin was included in the first batch of centralized procurement in 2018, the scale of the domestic market has been declining
.
Although Lipitor did not win the bid, Pfizer successfully maintained its leading position in the domestic market by reforming its marketing model
.
.
Since atorvastatin was included in the first batch of centralized procurement in 2018, the scale of the domestic market has been declining
.
Although Lipitor did not win the bid, Pfizer successfully maintained its leading position in the domestic market by reforming its marketing model
.
AstraZeneca's Teresa (osimertinib mesylate tablets) 2021H1 sales fell 14.
62% year-on-year
.
Teresa is the world's first third-generation advanced lung cancer targeted drug.
In 2018, its price was reduced by 70% and entered the national medical insurance negotiation catalog.
The price is 15,300 yuan per box/(80mg*30 tablets); Osimitinib first-line indications in 2020 Entering medical insurance, the price is reduced by 64% to 5580 yuan/box on the original basis
.
After the initial explosive growth, osimertinib experienced negative growth in the domestic market for the first time under the influence of price cuts and competing products
.
62% year-on-year
.
Teresa is the world's first third-generation advanced lung cancer targeted drug.
In 2018, its price was reduced by 70% and entered the national medical insurance negotiation catalog.
The price is 15,300 yuan per box/(80mg*30 tablets); Osimitinib first-line indications in 2020 Entering medical insurance, the price is reduced by 64% to 5580 yuan/box on the original basis
.
After the initial explosive growth, osimertinib experienced negative growth in the domestic market for the first time under the influence of price cuts and competing products
.
Shanghai: PPI injections soared 467%! Livzon, Yangtze River, Sansheng on the list
Shanghai: PPI injections soared 467%! Livzon, Yangtze River, Sansheng on the list Annual sales trend of terminal chemical drugs in Shanghai public hospitals (unit: 100 million yuan)
Source: Mi Nei.
com's chemical drug terminal competition pattern in key cities of public hospitals
com's chemical drug terminal competition pattern in key cities of public hospitals
According to data from Mi Nei.
com, the sales of terminal chemical drugs in Shanghai public hospitals in 2021H1 exceeded 9 billion yuan, a year-on-year increase of 3.
61%
.
From the perspective of the therapeutic field, the TOP3 sales categories are anti-tumor and immune modulators, digestive system and metabolic drugs, and systemic anti-infective drugs, accounting for 23.
04%, 15.
43%, and 13.
96% respectively
.
com, the sales of terminal chemical drugs in Shanghai public hospitals in 2021H1 exceeded 9 billion yuan, a year-on-year increase of 3.
61%
.
From the perspective of the therapeutic field, the TOP3 sales categories are anti-tumor and immune modulators, digestive system and metabolic drugs, and systemic anti-infective drugs, accounting for 23.
04%, 15.
43%, and 13.
96% respectively
.
2021H1 Shanghai Public Hospital's Top 10 Chemical Drug Brands
Source: Mi Nei.
com's chemical drug terminal competition pattern in key cities of public hospitals
com's chemical drug terminal competition pattern in key cities of public hospitals
Among the TOP10 brands, there are 4 anti-tumor drugs, and 2 plasma substitutes and infusions
.
From the perspective of sales changes, the sales of Livzon Group’s ilaprazole sodium for injection soared 466.
95%, Sanofi’s oxaliplatin for injection rose by more than 100%; sales of five brands declined, and Roche’s All three monoclonal antibodies are involved
.
.
From the perspective of sales changes, the sales of Livzon Group’s ilaprazole sodium for injection soared 466.
95%, Sanofi’s oxaliplatin for injection rose by more than 100%; sales of five brands declined, and Roche’s All three monoclonal antibodies are involved
.
Sanofi's leroxatin (oxaliplatin for injection) ranked first, with sales in 2021H1 increasing by 107.
58% year-on-year; Bayer's Xarelto (rivaroxaban tablets) ranked third, with 2021H1 sales increasing year-on-year 13.
04%
.
Oxaliplatin and rivaroxaban are the fifth batch of collectively harvested varieties.
Sanofi’s oxadine won the bid with the highest price, while Bayer’s Xarelto abandoned the bid.
In the end, many companies won the bid for rivaroxaban.
Up to 13 companies
.
With the implementation of the fifth batch of centralized procurement, the market structure of oxaliplatin and rivaroxaban will be reshuffled
.
58% year-on-year; Bayer's Xarelto (rivaroxaban tablets) ranked third, with 2021H1 sales increasing year-on-year 13.
04%
.
Oxaliplatin and rivaroxaban are the fifth batch of collectively harvested varieties.
Sanofi’s oxadine won the bid with the highest price, while Bayer’s Xarelto abandoned the bid.
In the end, many companies won the bid for rivaroxaban.
Up to 13 companies
.
With the implementation of the fifth batch of centralized procurement, the market structure of oxaliplatin and rivaroxaban will be reshuffled
.
Ilaprazole is a proton pump inhibitor and is currently the strongest class of drugs that inhibit gastric acid secretion
.
As the exclusive innovative drug of Livzon Group, ilaprazole enteric-coated tablets have been included in the national medical insurance category B, and ilaprazole sodium for injection entered the national medical insurance negotiation catalog at the end of 2019
.
In recent years, the market size of ilaprazole has continued to rise, and it has grown into a large variety of 1 billion yuan in Livzon Group
.
.
As the exclusive innovative drug of Livzon Group, ilaprazole enteric-coated tablets have been included in the national medical insurance category B, and ilaprazole sodium for injection entered the national medical insurance negotiation catalog at the end of 2019
.
In recent years, the market size of ilaprazole has continued to rise, and it has grown into a large variety of 1 billion yuan in Livzon Group
.
In addition to Livzon Group’s ilaprazole sodium for injection, the domestic brands on the list include Yangtze River Pharmaceutical’s Dezocine Injection and 3SBio’s Terpio (recombinant human thrombopoietin injection)
.
Dezocine is a powerful opioid analgesic used for all kinds of pain that require opioid analgesics
.
TPIAO is the only recombinant human thrombopoietin (rhTPO) product in the world today.
The semi-annual report of 3SBio shows that TPIAO's sales in 2021H1 exceeded 1.
5 billion yuan, an increase of 10.
7% year-on-year
.
.
Dezocine is a powerful opioid analgesic used for all kinds of pain that require opioid analgesics
.
TPIAO is the only recombinant human thrombopoietin (rhTPO) product in the world today.
The semi-annual report of 3SBio shows that TPIAO's sales in 2021H1 exceeded 1.
5 billion yuan, an increase of 10.
7% year-on-year
.
Guangzhou: Sales of breast cancer "magic drug" soared by 120% ! Qilu and Shiyao are on the list
Guangzhou: Sales of breast cancer "magic drug" soared by 120% ! Qilu and Shiyao are on the list Annual sales trend of terminal chemical drugs in public hospitals in Guangzhou (unit: 100 million yuan)
Source: Mi Nei.
com's chemical drug terminal competition pattern in key cities of public hospitals
com's chemical drug terminal competition pattern in key cities of public hospitals
According to data from Mi Nei.
com, the terminal chemical drug sales of public hospitals in Guangzhou in 2021H1 are close to 10 billion yuan, a year-on-year increase of 17.
07% and a year-on-year decline of more than 10%
.
From the perspective of the treatment field, the TOP3 sales categories are anti-tumor and immunomodulators, digestive system and metabolic drugs, blood and hematopoietic system drugs, accounting for 31.
79%, 13.
82%, and 12.
44% respectively
.
com, the terminal chemical drug sales of public hospitals in Guangzhou in 2021H1 are close to 10 billion yuan, a year-on-year increase of 17.
07% and a year-on-year decline of more than 10%
.
From the perspective of the treatment field, the TOP3 sales categories are anti-tumor and immunomodulators, digestive system and metabolic drugs, blood and hematopoietic system drugs, accounting for 31.
79%, 13.
82%, and 12.
44% respectively
.
2021H1 Guangzhou Public Hospital Terminal Chemical Drug Brand Top 10
Source: Mi Nei.
com's chemical drug terminal competition pattern in key cities of public hospitals
com's chemical drug terminal competition pattern in key cities of public hospitals
Among the TOP10 brands, there are 6 anti-tumor drugs, and 1 systemic antibacterial drug, hemostatic drug, blood substitute and perfusion fluid, and immunostimulant
.
The TOP5 brands are all anti-tumor drugs, and the sales of Sanofi’s oxaliplatin and AstraZeneca’s osimertinib both exceeded 100 million yuan
.
Roche still has 3 monoclonal antibodies on the list, the difference is that Pertuzumab replaced rituximab
.
.
The TOP5 brands are all anti-tumor drugs, and the sales of Sanofi’s oxaliplatin and AstraZeneca’s osimertinib both exceeded 100 million yuan
.
Roche still has 3 monoclonal antibodies on the list, the difference is that Pertuzumab replaced rituximab
.
Roche's breast cancer targeted drug Pattuzumab (Pertuzumab injection) squeezed into the TOP10 for the first time, and sales in 2021H1 increased by 122.
65% year-on-year
.
Pertuzumab is a second-generation targeted drug for HER2-positive breast cancer.
It was approved for marketing in China at the end of 2018 and entered the National Medical Insurance Negotiation List at the end of 2019.
The price is 4955 yuan per tube (420mg/14ml), which is more included in medical insurance.
Compared with the previous 18,800 yuan/branch, a decrease of 74%
.
Medical insurance negotiations promote the rapid increase in volume of this product.
In 2020, the sales of Pertuzumab in public hospitals in Guangzhou will increase by more than 4200%
.
65% year-on-year
.
Pertuzumab is a second-generation targeted drug for HER2-positive breast cancer.
It was approved for marketing in China at the end of 2018 and entered the National Medical Insurance Negotiation List at the end of 2019.
The price is 4955 yuan per tube (420mg/14ml), which is more included in medical insurance.
Compared with the previous 18,800 yuan/branch, a decrease of 74%
.
Medical insurance negotiations promote the rapid increase in volume of this product.
In 2020, the sales of Pertuzumab in public hospitals in Guangzhou will increase by more than 4200%
.
The domestic brands on the list include Qilu Pharmaceutical's Xinruibai (pegylated recombinant human granulocyte stimulating factor injection) and CSPC Ouyi's Domesu (doxorubicin hydrochloride liposome injection)
.
.
Pegylated recombinant human granulocyte stimulating factor injection is a long-acting baiyao.
According to data from Meinenet, the domestic long-acting baiyao market has continued to rise in recent years.
Currently, the product manufacturers include Qilu Pharmaceutical and CSPC.
, Hengrui Pharmaceutical , and New Times Pharmaceutical
.
Medicine MedicineAccording to data from Meinenet, the domestic long-acting baiyao market has continued to rise in recent years.
Currently, the product manufacturers include Qilu Pharmaceutical and CSPC.
, Hengrui Pharmaceutical , and New Times Pharmaceutical
.
Doxorubicin hydrochloride is an anthracycline antibiotic and a broad-spectrum anti-tumor drug.
It is mainly used for chemotherapy of multiple myeloma, lymphoma, ovarian cancer, and breast cancer
.
Doxorubicin Hydrochloride Liposome Injection is a high-end nano-preparation, and currently only three domestic companies have been approved for production, including CSPC Ouyi, Changzhou Jinyuan Pharmaceutical and Fudan Zhangjiang
.
Among them, CSPC Ouyi is the first company that has reviewed this product
.
Business enterprise It is mainly used for chemotherapy of multiple myeloma, lymphoma, ovarian cancer, and breast cancer
.
Doxorubicin Hydrochloride Liposome Injection is a high-end nano-preparation, and currently only three domestic companies have been approved for production, including CSPC Ouyi, Changzhou Jinyuan Pharmaceutical and Fudan Zhangjiang
.
Among them, CSPC Ouyi is the first company that has reviewed this product
.
